Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 5 | 2 | 7 |
| 1995 | 2 | 2 | 4 |
| 1996 | 6 | 0 | 6 |
| 1997 | 6 | 1 | 7 |
| 1998 | 5 | 2 | 7 |
| 1999 | 4 | 0 | 4 |
| 2000 | 7 | 2 | 9 |
| 2001 | 5 | 1 | 6 |
| 2002 | 0 | 1 | 1 |
| 2003 | 8 | 2 | 10 |
| 2004 | 5 | 5 | 10 |
| 2005 | 9 | 5 | 14 |
| 2006 | 5 | 4 | 9 |
| 2007 | 5 | 1 | 6 |
| 2008 | 8 | 4 | 12 |
| 2009 | 9 | 1 | 10 |
| 2010 | 5 | 5 | 10 |
| 2011 | 12 | 2 | 14 |
| 2012 | 4 | 1 | 5 |
| 2013 | 5 | 1 | 6 |
| 2014 | 6 | 2 | 8 |
| 2015 | 7 | 2 | 9 |
| 2016 | 7 | 3 | 10 |
| 2017 | 8 | 3 | 11 |
| 2018 | 9 | 1 | 10 |
| 2019 | 12 | 3 | 15 |
| 2020 | 6 | 6 | 12 |
| 2021 | 5 | 8 | 13 |
| 2022 | 1 | 5 | 6 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Adv. 2023 12 26; 7(24):7393-7401.
-
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma. Blood Adv. 2023 12 12; 7(23):7361-7368.
-
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. Blood Adv. 2023 09 12; 7(17):5038-5046.
-
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Adv. 2023 07 25; 7(14):3516-3529.
-
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma. Leuk Lymphoma. 2023 09; 64(9):1579-1582.
-
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023 06 13; 7(11):2287-2296.
-
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial. JAMA Oncol. 2023 05 01; 9(5):683-691.
-
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Am J Hematol. 2023 06; 98(6):900-912.
-
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). Oncotarget. 2023 01 26; 14:57-70.
-
Melphalan flufenamide for relapsed/refractory multiple myeloma. Drugs Today (Barc). 2022 Aug; 58(8):407-423.